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Abstract
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Purpose—To assess breast cancer screening utilization in Medicare beneficiaries with colorectal
and lung cancer versus cancer-free controls.
Methods—Female fee-for-service Medicare beneficiaries who were ≥67 years old and diagnosed
with lung or colorectal cancer between 2000 and 2011 and who reported to a Surveillance,
Epidemiology, and End Results (SEER) registry (case group) were followed for 2 years after their
diagnoses, unless death, a diagnosis of breast cancer, or the end of 2013 came first. A similar
number of cancer-free controls were individually matched to cases by age, race, registry region,
and follow-up time. Screening utilization was defined as the percentage of women with ≥1
screening mammogram during follow-up.

Author Manuscript

Results—Overall, 104,164 cases (48% colorectal, 52% lung; 30% advanced cancer) and 104,164
controls were included. Among women with lung or colorectal cancer, 22% underwent ≥1
screening mammogram versus 26% of controls (odds ratio [OR] 0.80; 95% confidence interval
[CI] 0.78–0.82). Stratified by cancer type, 28% of colorectal cancer cases versus 29% of controls
(OR 0.98; 95% CI 0.95–1.01) and 17% of lung cancer cases versus 23% of controls (OR 0.63;
95% CI 0.60–0.65) received ≥1 mammogram. When stratified by stage, 8% with advanced cancer
versus 18% of controls (OR 0.33; 95% CI 0.31–0.35) and 30% with early-stage cancer versus 30%
of controls (OR 1; 95% CI 0.97–1.02) underwent ≥1 mammogram.

Corresponding author and reprints: Gelareh Sadigh, MD, Department of Radiology and Imaging Sciences, Emory University School
of Medicine, 1364 Clifton Rd, Room 125 D, Atlanta, GA 30322; gsadigh@emory.edu.
The authors have no conflicts of interest related to the material discussed in this article.
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Conclusion—Screening mammography utilization rates are similar between Medicare
beneficiaries with early-stage cancer versus controls. Although the majority of patients with
advanced-stage cancer appropriately do not pursue screening mammography, a small number (8%)
continue with screening.
Keywords
Screening mammography; cancer survivorship period; utilization; population-based

INTRODUCTION

Author Manuscript

Advances in early cancer detection and treatment have led to an approximate 20% decrease
in mortality between 1991 and 2010 [1]. In general, cancer survivors are at increased risk of
developing second primary malignancies [2] from genetic syndromes, shared etiologic
factors, or late sequel of treatment. These second malignancies account for 16% of all cancer
diagnoses [3]. Lung and colorectal cancer survivorship, however, does not seem to increase
the risk of subsequent breast cancer [4–6]. Accordingly, breast cancer screening rates in
survivors of early-stage lung and colorectal cancer are expected to be similar to those in a
cancer-free population. However, life expectancy of cancer survivors varies by disease stage.
Routine screening may not benefit those presenting with advanced cancer, driving
unnecessary health care costs [7].

Author Manuscript

The utilization of cancer screening tests during cancer survivorship is multifactorial and
involves considerable discretion by the treating physician [8], who needs to assess the
patient’s life expectancy and communicate that prognosis to the patient. Sometimes,
screening tests are performed at patients’ requests, even if contrary to guidelines. Patients
sometimes use their primary cancer diagnosis as a behavior-changing event or use denial as
a coping strategy [7,9]. Furthermore, variation and uncertainty exist among health care
practitioners about the best use of cancer screening in patients with existing cancer
diagnoses.

Author Manuscript

Studies from over two decades ago reported a slight but not significant increase in screening
mammography utilization in colorectal cancer survivors after their cancer diagnosis [10,11].
Considerable interval changes in breast cancer screening utilization overall [12–15], breast
cancer screening guidelines [16,17], increased breast cancer awareness [18], and decreased
mortality of cancer survivors [1] warrants a re-evaluation of the rate, frequency, and interval
of screening mammography utilization in the broad population of patients with a new cancer
diagnosis (compared with a cancer-free population). In addition to understanding
contemporary rates of screening utilization, information about the distribution of screening
utilization by stage at diagnosis could guide initiatives to ensure more appropriate screening.
The purpose of this study was to compare utilization rates of breast cancer screening in
women 67 years or older with a new diagnosis of colorectal or lung cancer to screening rates
(1) in a cancer-free Medicare control group and (2) in the same patients in the 2 years before
their primary cancer diagnosis. We further compared utilization rates for individuals with
late- versus early-stage diagnoses and then explored predictors of screening mammography
within the case population.
J Am Coll Radiol. Author manuscript; available in PMC 2017 September 07.
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METHODS
Institutional Review Board approval and a waiver of informed consent were both obtained
for this HIPAA-compliant retrospective review of linked Surveillance, Epidemiology, and
End Results (SEER) Program and Medicare carrier claims data.
Data Source
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We used SEER-Medicare, a cancer registry and claims-based database of medical care
received by Medicare beneficiaries with cancer. The database includes SEER program
information from cancer registries in 13 states or metropolitan areas (18 registries covering
approximately 28% of the US population) and fee-for-service claims for covered health care
services (both Parts A and B benefits) for all SEER registry Medicare beneficiaries from the
time of a person’s Medicare eligibility until death [19,20]. The linkage of SEER with
Medicare data used for this study was last updated in 2014 [19].
Study Population

Author Manuscript

Cancer Cases—All Medicare-enrolled women 67 years or older registered in SEER
between 2000 and 2011 with a diagnosis of colorectal or lung cancer were assessed for
eligibility. These specific cancers were selected because they represent the most common
nonbreast malignancies in women [21]. We excluded all patients in whom colorectal or lung
cancer was not their first primary cancer, as well as those with an unknown month of cancer
diagnosis, a diagnosis reported only from autopsy or death certificate, a date of death before
date of diagnosis, or a death or breast cancer diagnosis within the first 3 months after the
colorectal or lung cancer diagnosis. To ensure complete claims capture, we only included
patients continuously enrolled in Medicare Parts A and B and not enrolled in a Medicare
HMO from 2 years before cancer diagnosis to a follow-up end date defined as 2 years and 3
months after diagnosis, a diagnosis of breast cancer, death, or the censoring date of
December 31, 2013, whichever came first. We defined patients with advanced cancer as
those with SEER-derived American Joint Committee on Cancer (AJCC) [22] stage IV
colorectal cancer and IIIB-IV lung cancer, which have an estimated overall 5-year survival
of 5% and 3%, respectively [7].
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Cancer-Free Controls—A matched cohort of female fee-for-service Medicare enrollees
without cancer with sufficiently complete demographic information was identified from a
random 5% sample of Medicare fee-for-service beneficiaries residing in SEER areas. Each
cancer patient was individually matched to a cancer-free control by birth year, race, and
registry region. As with cancer cases, we only included controls continuously enrolled in
Medicare Parts A and B between the date of the corresponding case diagnosis and case
follow-up end date. Each control had exactly the same amount of follow-up time as her
corresponding cancer case.
Screening Mammography Utilization
We restricted the analysis to billing codes that specifically identify screening (rather than
diagnostic) mammography. Screening mammography services were identified using Current
Procedural Terminology (CPT) codes 77057 and 76092 and Healthcare Common Procedure

J Am Coll Radiol. Author manuscript; available in PMC 2017 September 07.
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Coding System (HCPCS) codes G0202 and G0203 [23]. All duplicate claims were
eliminated by matching patient identifier, examination date, and CPT or HCPCS code.
Screening utilization rates were defined as the percentage of women undergoing at least one
screening mammogram between follow-up start and end dates. To help ensure a screening
mammogram was not part of a colorectal or lung cancer diagnosis workup, the follow-up
start date was defined as 3 months after cancer diagnosis for all study outcomes and
extended for a maximum of 2 years beyond that date.
Study Outcomes

Author Manuscript

The primary outcome was the utilization of screening mammography in Medicare
beneficiaries with colorectal and lung cancer versus a cancer-free control group between the
follow-up start and end dates. We further performed time to event analysis to estimate
screening rates over time.
A secondary outcome was the utilization of screening mammography in Medicare
beneficiaries with colorectal or lung cancer within 2 years before versus 2 years after
diagnosis.
Statistical Analysis

Author Manuscript

Screening mammography utilization was compared using McNemar’s test for cancer cases
versus cancer-free controls (primary outcome) and before versus after cancer diagnosis
(secondary outcome). Odds ratios (ORs) were calculated using the Mantel-Haenszel method
for matched pairs [24]. A time to event analysis was further performed for the primary
outcome by plotting the cumulative incidence of a screening event over a 2-year window
after diagnosis for cases and controls. Estimated screening event rates and 95% confidence
intervals (CIs) over time are reported.
Predictors of screening mammography utilization among cases was assessed using
multivariable logistic regression analyses, modeling cancer site (lung, colon), stage (0-IV),
age at diagnosis (65–69 years, 70–74 years, 75–79 years, >80 years), race or ethnicity
(white, African American, other), geographic region (Northeast, Southeast, Midwest, West),
marital status (married, not married), and SEER poverty index (0%–<5%, 5%–<10%, 10%–
<20%, 20%–100%). Multicollinearity was checked using variance inflation factors.
Statistical analyses were conducted using SAS version 9.2 (SAS Institute Inc, Cary, North
Carolina, USA). All significance tests were two-sided and used a 5% level of significance.

Author Manuscript

RESULTS
Study Population Characteristics
Overall, 104,164 cancer cases and 104,164 matched controls were included for the primary
outcome analysis (Fig. 1). Baseline characteristics of cancer cases are shown in Table 1.
Forty-eight percent of patients had colorectal and 52% had lung cancer. Mean age at
diagnosis was 78 (standard deviation 7), ranging from 67 to 107, and did not vary
remarkably by cancer site; 87% of patients were white and 35% were married. By study
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design, selected demographics (age, race, and region) of control cases mirrored those of
cancer cases.
Utilization of Screening Mammography in Cases Versus Controls
Utilization of screening mammography is shown in Table 2. Among women with newly
diagnosed colorectal or lung cancer, 22% underwent at least one screening mammogram
versus 26% of controls (OR 0.80; 95% CI 0.78–0.82) within the 2-year follow-up window.
Stratified by cancer type, 28% of colorectal cancer cases versus 29% controls (OR 0.98;
95% CI 0.95–1.01) and 17% of lung cancer cases versus 23% controls (OR 0.63; 95% CI
0.60–0.65) received at least one mammogram. When further stratified by stage of the case,
8% with newly diagnosed advanced cancer versus 18% of controls (OR 0.33; 95% CI 0.31–
0.35) and 30% with newly diagnosed early-stage cancer versus 30% of controls (OR 1; 95%
CI 0.97–1.02) underwent at least one mammogram.
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Appendix 1 and Figure 2 show time to event analysis for screening mammography rates at 6,
12, 18, and 24 months within the 2-year follow-up window. Screening rates in cancer
patients are slightly lower than controls regardless of time interval. This gap in event rates is
higher in lung cancer patients, but very minimal in colorectal cancer patients. In advanced
cancer patients, the screening rate difference between cases and controls increases over time.
In early-stage cancer, the difference is minimal and does not change over time.
Utilization of Screening Mammography Changes Before and After Cancer Diagnosis
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Receipt of at least one screening mammogram within 2 years after diagnosis of colorectal or
lung cancer compared with 2 years before diagnosis was 22% versus 38% (OR 0.28; 95% CI
0.27–0.29). Stratified by cancer type, this was 28% versus 35% for colorectal (OR 0.59;
95% CI 0.57–0.61) and 17% versus 42% for lung cancer patients (OR 0.13; 95% CI 0.13–
0.14). When stratified by stage, only 8% of patients with newly diagnosed advanced cancer
received a screening mammogram within 2 years after diagnosis versus 40% within 2 years
before diagnosis (OR 0.05; 95% CI 0.05–0.06). In comparison, 30% with newly diagnosed
early-stage cancer received a screening mammogram within 2 years after diagnosis as
opposed to 39% within 2 years before diagnosis (OR 0.48; 95% CI 0.47–0.50; Table 2).
Independent Predictors of Screening Mammography
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Independent predictors of screening mammography are shown in Appendix 2. Higher
screening mammography utilization within 2 years after cancer diagnosis was associated
with colorectal compared with lung cancer (OR 2), lower AJCC stage (OR 4 for occult
cancer, OR 8.1 for stage I, OR 4.3 for II, and OR 3.3 for III when compared with stage IV),
younger age (OR 3.6 for <70; OR 3.1 for 70–74; OR 2.3 for 75–80 when compared with age
> 80), white race (OR 1.2 compared with African American), being married (OR 1.5), lower
poverty (OR 1.5 for poverty index <5%; OR 1.4 for index 5%–<10%; OR 1.1 for index
10%–<20% when compared with index 20%–100%), and geography (OR 1.2 for Southeast
and West when compared with Northeast; all P < .05). Except for race and geography,
similar independent predictors were identified when analyses were performed for colorectal
and lung cancer.
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DISCUSSION
In this study of screening mammography in fee-for-service Medicare beneficiaries with
colorectal and lung cancer, cancer patients have slightly lower utilization rates compared
with a cancer-free control population. In early-stage cancer patients, this difference is
minimal. In patients with advanced cancer, utilization rates drop significantly over time
compared with control patients. Nonetheless, 8% continue screening mammography, despite
low 5-year survival likelihoods (5% for colorectal cancer and 3% for lung cancer) [7].

Author Manuscript

Prior studies have shown that some cancer survivors remain preoccupied about their health
[25] and make positive health-protective changes (eg, adherence to follow-up tests and
visits) and health-promoting behavior (eg, smoking cessation, healthy diet, exercise) after
cancer diagnoses [25–28]. This preoccupation could also result in a desire for increased
screening, even when additional cancer risk is not present. For example, overutilization of
Pap smear screening was reported among women who have undergone hysterectomy [29].
Interestingly, among early-stage cancer survivors, we did not show increased screening rates,
compared with matched cancer-free controls. Furthermore, when screening rates were
compared with the same patient’s utilization of screening mammogram before her cancer
diagnosis, utilization slightly decreased, which could be partly due to aging or death in the
cases postdiagnosis, resulting in a shorter window for utilization assessment. Re-analyses of
breast cancer screening utilization among early cancer patients should be conducted as
additional SEER data become available to assess whether breast cancer screening continues
to be appropriate in the late survivorship period.

Author Manuscript
Author Manuscript

In advanced cancer patients, screening rates were significantly lower than in a cancer-free
population, and those rates diverged over time. Furthermore, screening rates after cancer
diagnoses dropped significantly compared with patients’ prediagnosis screening rates. Both
are likely mainly due to the predicted decreased survival as a result of advanced cancer,
resulting in a median follow-up time of 6 months. Although the majority of advanced-stage
cancer patients (92%) appropriately do not pursue screening mammography, a small
proportion may continue to undergo screening mammography. Both the Society of Breast
Imaging and the ACR recommend cessation of breast cancer screening in women with life
expectancies shorter than 5 to 7 years [30]. A definitive explanation for our results cannot be
gleaned from our retrospective analysis, but a variety of factors could be contributing.
Ongoing screening in some advanced cancer patients might be due to fear of another cancer
(enhancing their desire for screening even in the absence of evidence of potential benefit),
denial of their primary cancer prognosis, using their primary cancer diagnosis as a behaviorchanging event [7,9], or inadequate communication about life expectancy and the lack of
screening benefit with referring physician [8].
Our results are thus consistent with prior reports of screening mammography rates ranging
from 9% among Medicare beneficiaries with advanced cancers and median survival of less
than 2 years [7] to 34% in National Health Institute Survey participants with more than 75%
risk of mortality within 5 years, regardless of prior cancer [31]. Therefore, age alone is
insufficient in determining appropriateness of screening [31]. However, whether guideline
changes are sufficient to improve appropriate screening utilization is unclear. There are
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several reports of screening mammography utilization among women older than 75 years
[32] despite lack of evidence for screening benefit and the possibility of overdiagnosis and
overtreatment [17]. Both patients and referring physicians likely play a role in the choice to
continue screening [33]. For many patients, screening cessation was seen as a major decision
but continuing screening was not, and a physician’s recommendation to stop screening may
in fact threaten patient trust [34]. For these reasons, referring physician surveys have shown
that discussions about screening discontinuation can be uncomfortable and time-consuming
[35].

Author Manuscript

The utilization of cancer screening in patients with short life expectancies could cause net
harm to both the patients and their family or caregivers due to complications from
subsequent diagnostic procedures, overtreatment of clinically unimportant cancers,
psychological stress associated with overdiagnosis of a cancer that will not cause death or
symptoms, and possibly temporary anxiety associated with false-positive results [32,36].
Studies estimate that 1 in 15 screening mammograms are false-positives [32,37] and 1 in 3
breast cancers detected are overdiagnosed [38]. For individuals with advanced cancer and
short life expectancies, additional diagnostic workup, whether it ends up being a falsepositive or true cancer that would likely never become clinically significant within 5 years,
probably represents wasteful care and can also potentially result in psychological stress [39]
in a patient with an already established cancer diagnosis.
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Finally, cancer screening in patients with short life expectancies has health resource
implications. More than 25% of Medicare dollars are spent at the end of life [40], and cancer
consumes a great proportion of overall Medicare expenditures [41], with a 1- to 3-fold
increase in monthly health care utilization rates starting from 3 to 5 months before a cancer
diagnosis [42]. Mean 5-year net health care costs for Medicare-covered women with
colorectal cancer have been estimated as $35,000 [43]. Furthermore, there are indirect costs
associated with cancer screening and follow-up visits, such as cost of transportation to and
from medical appointments, work absence and lost productivity, and child care coverage
[44]. One strategy in limiting health care cost is to systematically identify unnecessary care
that does not provide meaningful benefit [7]. Identification of wasteful care is challenging
because each patient’s circumstances are unique, making it difficult to reliably define
episodes of overuse [7]. Although costs are rarely the sole reason that guidelines set limits
on screening [36], in cancer patients with short life expectancies, overscreening,
overdetection, and overtreatment are examples of care unlikely to provide net benefit to
patients. A more thoughtful decision to screen will likely partially reduce the costs of care in
cancer patients.
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When stratified by cancer type, we found that overall women with colorectal cancer are
more likely to undergo screening mammography than those with lung cancer. This is likely
partially due to later stages of cancer at diagnosis among patients with lung cancer compared
with colorectal cancer. However, after adjusting the utilization based on staging and other
patient demographics, screening mammography use remained 2-fold higher in colorectal
cancer patients. As expected, factors associated with longer survival (such as younger age
and lower AJCC stage) were associated with higher utilization rates of screening
mammography. Furthermore, the sources of screening disparity among cancer survivors
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were similar to the general population, namely, race [45], marital [46] and economic status
[47], as well as geography [45].
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This study has several limitations due to use of the SEER-Medicare data source. First,
screening mammography use was determined using CPT or HCPCS billing codes for
screening mammography. Some studies suggest underestimation of screening
mammography rates when solely using screening mammography codes, with uncertainty in
distinguishing screening from diagnostic mammograms [48]. To avoid overestimating
screening mammography utilization, this study thus focused only on screening billing codes.
Second, the overall screening mammography rate is lower compared with other studies with
younger mean age population [49,50], probably because it included only Medicare
beneficiaries 67 years and older. Finally, although 8% of advanced cancer patients continue
to undergo screening mammography, it is unclear what proportion are among the small
percentage of advanced cancer patients surviving beyond the recommended 5 years for
screening mammography by societal guidelines.

CONCLUSION

Author Manuscript

In summary, the study results show that although there is no difference in screening
mammography utilization among women with early-stage cancer versus cancer-free
controls, 8% of women with advanced cancer continue screening mammography after their
diagnosis compared with 18% in a cancer-free control matched on follow-up time and 40%
of women within 2 years before diagnosis. Furthermore, women with colorectal cancer
(compared with lung cancer) and certain sociodemographic characteristics are more likely to
undergo screening mammography. Identifying areas of potential inappropriate utilization
could help target interventions to improve clinical practice. Efforts should be made in
ensuring appropriate utilization of screening mammography in the small proportion of
advanced cancer patients who undergo this test, based on their individual survival rates and
response to therapy. Such information about screening test utilization in cancer patients with
short life expectancy could guide cancer screening guidelines and Medicare coverage
decisions to reduce the costs of cancer care.
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Appendix 1
Time to event analysis for screening mammography in cases and control patients
Both Cancers
Case

Colorectal Cancer
Ctrl

Case

Ctrl

Lung Cancer
Case

Ctrl

All stages
6 months

11.1 (10.9–11.3)

15.3 (15–15.5)

12.7 (12.4–13)

14.7 (14.4–15.1)

9.5 (9.2–9.8)

15.9 (15.6–16.3)

12 months

23.9 (23.6–24.3)

27.9 (27.6–28)

26 (25.6–26.5)

27 (26.6–27.4)

21.4 (21–21.9)

29.1 (28.6–29.6)

18 months

29.8 (29.5–30.1)

33 (32.7–33.4)

31.7 (31.3–32.2)

31.9 (31.4–32.3)

27.6 (27–28.1)

34.6 (34–35.1)

24 months

34 (33.7–34.4)

36.3 (36–36.7) 35.7

(35.2–36.2)

35.2 (34.7–35.7)

32.2 (32.6–32.8)

37.9 (37.4–38.5)

Advanced stage (stage IV colorectal and stage IIIB-IV lung cancer)
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6 months

5.4 (5–5.7)

15.4 (14.9–16)

4.4 (3.9–5.1)

14.9 (13.9–16)

5.6 (5.3–6)

16 (15.4–16.6)

12 months

12.9 (12.3–13.5)

27.9 (27.1–28.7)

11.6 (10.6–12.7)

27.1 (25.6–28.5)

12.8 (12.1–13.5)

29.2 (28.3–31.2)

18 months

17.5 (16.7–18.3)

32.4 (31.5–33.3)

15.5 (14.2–16.8)

31.5 (29.8–33.1)

17.1 (16.2–18)

34.3 (33.2–35.3)

24 months

21.1 (20.2–22.1)

35.7 (34.7–36.7)

19.1 (17.6–20.7)

35 (33.2–36.8)

20.8 (16.7–21.9)

37.6 (36.4–38.7)

6 months

13.9 (13.6–14.2)

15.2 (14.9–15.5)

13.9 (13.6–14.3)

14.9 (14.5–15.2)

12.5 (12.1–12.9)

16.1 (15.6–16.6)

12 months

28.2 (27.8–28.7)

27.9 (27.5–28.3)

27.9 (27.5–28.4)

27.3 (26.8–27.7)

26.7 (26–27.3)

29.5 (28.8–30.1)

18 months

34.4 (33.9–34.8)

33.1 (32.7–33.6)

33.7 (33.3–34.2)

32.2 (31.7–32.7)

33.6 (32.9–34.3)

35.2 (34.5–35.9)

24 months

38.5 (38–39)

36.5 (36.1–37)

37.7 (37.2–38.2)

35.5 (35–36)

38.4 (37.7–39.2)

38.6 (37.9–39.3)

Early stage

Cumulative screening rates at each time point are shown in percentage and 95% confidence intervals. Ctrl = control.
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Independent predictors of screening mammography in patients with newly diagnosed
colorectal or lung cancers within 2 years after diagnosis
Both Cancers, OR (95%
CI)

Colorectal Cancer, OR
(95% CI)

Lung Cancer, OR (95% CI)

2 (2–2.1)
(P < .001)

NA

NA

Cancer type
Colorectal vs lung

AJCC staging (reference “stage 4”)
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0

4 (3.8–4.4)
(P < .001)

6 (5.3–6.6)
(P < .001)

2.6 (2.3–2.9)
(P < .001)

1

8.1 (7.6–8.6)
(P < .001)

8 (7.2–8.8)
(P < .001)

8.8 (8.2–9.4)
(P < .001)

2

4.3 (4.1–4.6)
(P < .001)

5.5 (5–6)
(P < .001)

3.4 (3.1–3.7)
(P < .001)

3

3.3 (3.1–3.5)
(P < .001)

4.7 (4.2–5.2)
(P < .001)

2.4 (2.2–2.7)
(P < .001)

65–69

3.6 (3.4–3.8)
(P < .001)

4.2 (3.9–4.5)
(P < .001)

2.8 (2.6–3)
(P < .001)

70–74

3.1 (3–3.2)

3.6 (3.3–3.8)

2.4 (2.2–2.6)

Age (reference “age > 80”)
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75–79

Both Cancers, OR (95%
CI)

Colorectal Cancer, OR
(95% CI)

Lung Cancer, OR (95% CI)

(P < .001)

(P < .001)

(P < .001)

2.3 (2.2–2.4)
(P < .001)

2.4 (2.3–2.6)
(P < .001)

1.9 (1.8–2.1)
(P < .001)

1.5 (1.5–1.6)
(P < .001)

1.5 (1.4–1.6)
(P < .001)

Marital status (reference “not married”)
Married

1.5 (1.5–1.6)
(P < .001)

Race (reference “African American”)
White

1.2 (1.1–1.2)
(P < .001)

1.3 (1.2–1.4)
(P < .001)

1 (0.9–1.1)
(P .62)

Other

1 (0.9–1.1)
(P = .41)

0.9 (0.8–1.1)
(P = .49)

1 (0.8–1.1)
(P = .66)

Author Manuscript

Poverty index (reference “20–100%”)
0%–<5%

1.5 (1.4–1.6)
(P < .001)

1.5 (1.4–1.6)
(P < .001)

1.5 (1.4–1.7)
(P < .001)

5%–<10%

1.4 (1.2–1.4)
(P < .001)

1.4 (1.3–1.5)
(P < .001)

1.3 (1.2–1.5)
(P < .001)

10%–<20%

1.1 (1.1–1.2)
(P < .001)

1.2 (1.1–1.3)
(P < .001)

1.1 (1–1.2)
(P = .009)

SEER Registry (reference “Northeast”)

Author Manuscript

Midwest

1 (1–1.2)
(P = .43)

1.1 (1–1.2)
(P < .001)

0.9 (0.8–1)
(P = .01)

Southeast

1.2 (1.2–1.3)
(P < .001)

1.4 (1.3–1.5)
(P < .001)

1 (1–1.1)
(P = .36)

West

1.2 (1.2–1.3)
(P < .001)

1.3 (1.2–1.4)
(P < .001)

1.1 (1–1.2)
(P = .02)

AJCC = American Joint Committee on Cancer; CI = confidence interval; OR = odds ratio; SEER = Surveillance,
Epidemiology, and End Results.
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TAKE-HOME POINTS
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▪

There is appropriate utilization of screening mammography among earlystage cancer survivors.

▪

Eight percent of women with advanced cancer and short life expectancy
continue screening mammography after their diagnosis compared with 18%
in a matched cancer-free control and 40% of women within 2 years before
diagnosis.

▪

Higher screening mammography utilization was associated with colorectal
compared with lung cancer, lower AJCC stage, younger age, white race,
being married, and more favorable economic status.

▪

The utilization of cancer screening in patients with short life expectancies has
health resource implications and could cause net harm to patients due to
complications from subsequent diagnostic procedures, overdiagnosis, and
overtreatment.

▪

Identifying potential areas of overutilization may help target interventions to
reduce low-yield care.
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Fig 1.

Study flowchart for primary outcome analysis. CRC = colorectal cancer; DoD = date of
death; Dx = diagnosis; SEER = Surveillance, Epidemiology, and End Results.
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Fig 2.
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Plots showing time to event analysis for screening mammography in cases (continuous line)
and control (interrupted line) patients for (a) all patients, (b) advanced cancer patients, (c)
early-stage cancer patients, (d) colorectal cancer patients, and (e) lung cancer patients.
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Baseline characteristics of cancer cases
Characteristics*

Both Cancers (N = 104,164)

Colorectal Cancer (N = 50,432)

Lung Cancer (N = 53,732)

78 (7)

79 (7)

76 (6)

White

90,492 (87)

43,124 (85)

47,368 (88)

Black

8,356 (8)

4,372 (9)

3,984 (7)

Other

5,316 (5)

2,936 (6)

2,380 (5)

Married

34,551 (35)

16,384 (34)

18,167 (35)

Not Married

64,897 (65)

31,478 (66)

33,419 (65)

Northeast

24,113 (23)

12,329 (25)

11,784 (22)

Midwest

23,284 (22)

11,058 (22)

12,226 (23)

Southeast

35,296 (34)

16,292 (32)

19,004 (35)

West

21,471 (21)

10,753 (21)

10,718 (20)

0–<5%

27,019 (26)

13,222 (26)

13,797 (26)

5–<10%

28,595 (28)

13,875 (28)

14,720 (27)

10–<20%

29,129 (28)

13,994 (28)

15,135 (28)

20–100%

19,138 (18)

9,182 (18)

9,956 (19)

Age at diagnosis, y (SD)
Race, N (%)

Marital status, N (%)

Author Manuscript

SEER registry, N (%)

Poverty index, N (%)

AJCC staging, N (%)

Author Manuscript

0 or occult

9,269 (10)

5,203 (11)

4,066 (8)

1

21,988 (23)

10,643 (22)

11,345 (24)

2

24,541 (25)

17,668 (37)

6,873 (14)

3

15,983 (17)

7,499 (16)

8,484 (18)

4

24,117 (25)

6,625 (14)

17,492 (36)

Advanced stage cancer,† N (%)
Yes

28,669 (30)

6,625 (14)

22,044 (46)

No

67,120 (70)

41,013 (86)

26,107 (54)

AJCC = American Joint Committee on Cancer; SD = standard deviation; SEER = Surveillance, Epidemiology, and End Results.

*

There were missing data for variables marital status, poverty, AJCC staging, and presence of advanced-stage cancer.

†

Author Manuscript

Advanced-stage cancer includes stage IV colorectal cancer and stage IIIB-IV lung cancer.
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23,278 (22)

26,663 (26)

104,164

Ctrl,
N (%)

0.80 (0.78–0.82)
P < .001

OR (95% CI)

24

6

28,669

20,013 (30)

2,223 (8)

20,021 (30)

67,120

5,122 (18)

1 (0.97–1.02)
P = .96

0.33 (0.31–0.35)
P < .001

24

8

6,625

24

13,312 (32)

566 (9)

14,338 (28)

Case,
N (%)

12,737 (31)

41,013

1,253 (19)

14,525 (29)

50,432

Ctrl,
N (%)

1.08 (1.05–1.12)
P < .001

0.34 (0.30–0.38)
P < .001

0.98 (0.95–1.01)
P = .15

OR (95% CI)

19

5

22,044

10

f/u
(Months)

Case screening rates are similar to postdiagnosis screening rates in Table 3. CI = confidence interval; Ctrl = control; f/u = median follow-up; OR = odds ratio.

Screening rates

N

Early stage

Screening rates

N

Advanced stage (stage IV colorectal and stage IIIB-IV lung cancer)

Screening rates

N

All stages

Case,
N (%)

f/u
(Months)

Author Manuscript

f/u
(Months)

Colorectal Cancer

Author Manuscript

Both Cancers

6,701 (26)

1,657 (8)

8,940 (17)

Case,
N (%)

7,284 (28)

26,107

3,869 (18)

12,138 (23)

53,732

Ctrl,
N (%)

Lung Cancer

1.15 (1.10–1.20)
P < .001

0.33 (0.30–0.35)
P < .001

0.63 (0.60–0.65)
P < .001

OR (95% CI)

Author Manuscript

Utilization of screening mammography during follow-up period

Author Manuscript
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39,888 (38)

23,278 (22)

104,164

Post-dx, N (%)

0.28 (0.27–0.29)
P < .001

OR (95% CI)

26,120 (39)

11,385 (40)

20,013 (30)

67,120

2,223 (8)

28,669

0.48 (0.47–0.50)
P < .001

0.05 (0.05–0.06)
P < .001

14,710 (36)

2,043 (31)

17,464 (35)

Pre-dx, N (%)

13,312 (32)

41,013

566 (9)

6,625

14,338 (28)

50,432

Post-dx, N (%)

Colorectal Cancer

0.75 (0.72–0.78)
P < .001

0.11 (0.09–0.13)
P < .001

0.59 (0.57–0.61)
P < .001

OR (95% CI)

Postdiagnosis screening rates are similar to case screening rates in Table 2. CI = confidence interval; dx = diagnosis; OR, odds ratio.

Screening rates

N

Early stage

Screening rates

N

Advanced stage (stage IV colorectal and stage IIIB-IV lung cancer)

Screening rates

N

All stages

Pre-dx, N (%)

Both Cancers

Author Manuscript

Utilization of screening mammography before and after cancer diagnosis

11,410 (44)

9,342 (42)

22,424 (42)

Pre-dx, N (%)

6,701 (26)

26,107

1,657 (6)

22,044

8,940 (17)

53,732

Post-dx, N (%)

Lung Cancer

0.25 (0.24–0.26)
P < .001

0.04 (0.03–0.04)
P < .001

0.13 (0.13–0.14)
P < .001

OR (95% CI)

Author Manuscript
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